SUPNのニュース
Supernus Pharmaceuticals pays out $402M senior convertible notes 2023/04/04 07:44:22 Seeking Alpha
Biopharmaceutical company, Supernus Pharmaceuticals (SUPN) has paid out the total principal amount due of $402.5M under its 0.625% convertible senior notes due 2023.This is in addition…
Supernus Pharmaceuticals PT Lowered to $45 at Piper Sandler 2023/03/01 09:42:15 Investing.com
https://www.investing.com/news/pro/supernus-pharmaceuticals-pt-lowered-to-45-at-piper-sandler-432SI-3018158
Supernus Pharmaceuticals reports Q4 results, sees FY 2023 revenue in-line 2023/02/28 21:27:57 Seeking Alpha
Supernus Pharmaceuticals press release (SUPN): Q4 GAAP EPS of $0.43.Revenue of $167.33M (+5.2% Y/Y).Sees FY 2023 revenue of $580M to $620M
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results 2023/02/28 21:05:00 GlobeNewswire
1 Includes net product sales reported by Adamas Pharmaceuticals prior to the acquisition of Adamas by Supernus Pharmaceuticals in November 2021.
Supernus: Earnings Yearnings (NASDAQ:SUPN) 2023/02/10 14:20:00 Seeking Alpha
Supernus is pulling back after its strong post Q3, 2022 run. See why SUPN''s Q4 earnings should be particularly interesting for shareholders.
Supernus Pharmaceuticals PT Lowered to $45 at Piper Sandler 2023/03/01 09:42:15 Investing.com
https://www.investing.com/news/pro/supernus-pharmaceuticals-pt-lowered-to-45-at-piper-sandler-432SI-3018158
Supernus Pharmaceuticals reports Q4 results, sees FY 2023 revenue in-line 2023/02/28 21:27:57 Seeking Alpha
Supernus Pharmaceuticals press release (SUPN): Q4 GAAP EPS of $0.43.Revenue of $167.33M (+5.2% Y/Y).Sees FY 2023 revenue of $580M to $620M
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results 2023/02/28 21:05:00 GlobeNewswire
1 Includes net product sales reported by Adamas Pharmaceuticals prior to the acquisition of Adamas by Supernus Pharmaceuticals in November 2021.
Supernus: Earnings Yearnings (NASDAQ:SUPN) 2023/02/10 14:20:00 Seeking Alpha
Supernus is pulling back after its strong post Q3, 2022 run. See why SUPN''s Q4 earnings should be particularly interesting for shareholders.
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023 2023/02/09 23:15:00 GlobeNewswire
ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2022 after the market closes on Tuesday, February 28, 2023.
Supernus Pharmaceuticals PT Raised to $38 at Stifel 2023/01/04 13:12:02 Investing.com
https://www.investing.com/news/pro/supernus-pharmaceuticals-pt-raised-to-38-at-stifel-432SI-2973111
Supernus Pharmaceuticals PT Raised to $45 at Jefferies, Assumes Buy 2023/01/03 10:06:01 Investing.com
https://www.investing.com/news/pro/supernus-pharmaceuticals-pt-raised-to-45-at-jefferies-assumes-buy-432SI-2972086
Supernus Pharmaceuticals PT Raised to $45 at Jefferies 2023/01/02 08:30:02 Investing.com
https://www.investing.com/news/pro/supernus-pharmaceuticals-pt-raised-to-45-at-jefferies-432SI-2971734